| Overview |
| bs-6829R |
| MGEA5 Polyclonal Antibody |
| WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Dog, Sheep, Pig, Horse, Rabbit |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human MGEA5 |
| 756-850/916 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 10724 |
| Cytoplasm, Nucleus |
| Bunctional protein NCOAT; Glycoside hydrolase O-GlcNAcase; HAT; HEXC; Hexosaminidase C; Histone acetyltransferase; KIAA0679; MEA5; Meningioma expressed antigen 5; Meningioma-expressed antigen 5; MGEA 5; Mgea5; N-acetyl-beta-D-glucosaminidase; N-acetyl-beta-glucosaminidase; NCOAT; NCOAT_HUMAN; Nuclear cytoplasmic O GlcNAcase and acetyltransferase; Nuclear cytoplasmic O-GlcNAcase and acetyltransferase; O-GlcNAcase; OGA; NCOAT_HUMAN. |
| The dynamic modification of cytoplasmic and nuclear proteins by O-linked N-acetylglucosamine (O-GlcNAc) addition and removal on serine and threonine residues is catalyzed by OGT (MIM 300255), which adds O-GlcNAc, and MGEA5, a glycosidase that removes O-GlcNAc modifications (Gao et al., 2001 [PubMed 11148210]).[supplied by OMIM, Mar 2008]. |
| Application Dilution |
| WB |
1:300-5000 |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz